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Hemorrhagic Bullous Dermatosis
Bhuvanesh Govind, MD, Luis Eraso, MD, Esteban Gnass, MD, Geno Merli, MD
The patient is a 64 year old man with active primary central 
nervous system B-cell lymphoma who was hospitalized 
for management of a right lower extremity traumatic injury 
complicated by a calf hematoma. During the hospital 
stay, the patient was diagnosed with a provoked left 
lower extremity deep vein thrombosis (DVT) and treated 
initially with therapeutic dosing of enoxaparin. Five days 
after low molecular weight heparin (LMWH) initiation, 
gradual development of tense, well-circumscribed bullae 
were noted to appear on his arms and hands bilaterally, 
ranging from 0.5 cm to 1.5 cm in diameter. These lesions 
were both nonpruritic and nontender with no significant 
surrounding erythema (Figure 1). Bullae were located 
distal to the site of enoxaparin injections. Aside from a 
normocytic normochromic anemia related to chronic 
medical conditions, results of platelet counts, creatinine 
levels, and coagulation profiles remained unremarkable. 
A shave biopsy of one of the lesions revealed an intraepi-
dermal collection of red blood cells without evidence 
of thrombotic or vasculitic changes (Figures 2 & 3). 
enoxaparin dose was reduced several days after lesion 
onset due to increasing calf hematoma size, in an effort 
to balance anticoagulation benefit for the DVT with risk 
Figure 1. Hemorrhagic Bullosis dermatosis. Well-circumscribed, 
tense, nontender bullae with no significant surrounding erythema.
Figure 2. Intraepidermal collection of red blood cells, beneath the 
keratin layer. (4x power)
Figure 3. No evidence of thrombotic or vasculitic changes. 
Hemorrhagic collection with occasional neutrophils. (210x power) 
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of continued bleeding into the hematoma. The bullae 
started to regress approximately two weeks after onset, 
eventually crusting over. The patient was eventually 
discharged home.
We present a case of hemorrhagic bullous dermatosis, 
which is a rare type of cutaneous reaction to heparins 
with only a handful of cases reported in the literature. 
Delayed-type (type IV) hypersensitivity and immune-
mediated (heparin-induced thrombocytopenia) 
mechanisms are the most common causes of cutaneous 
complications attributed to heparin products.1 Type IV 
cutaneous hypersensitivity reactions are non-antibody 
mediated and typically occur several days to weeks 
following drug exposure. They may manifest as isolated 
or multiple erythematous plaques with papulovesicles 
or scaling. Heparin-induced thrombocytopenia, on the 
other hand, can induce skin erythema that progresses 
to hemorrhage and subsequent tissue necrosis.1 Several 
unusual and rare dermatologic manifestations have 
been reported in the literature with a broad differential 
diagnosis including pustulosis, toxic epidermal 
necrolysis, arthus reaction, baboon syndrome, hypere-
osinophilia, and calcinosis cutis.1,3
There have only been ten cases reported in the 
literature regarding the clinical setting and course of 
hemorrhagic bullosis. Mechanisms underlying the 
pathogenesis of these lesions have not been clearly 
elucidated, although a hypersensitivity reaction has 
been suspected.1,4,5 The histopathology of the bullae 
reveal intraepidermal collections of red blood cells 
without any thrombotic or vasculitic changes. Direct 
immunofluorescence and heparin platelet factor 4 have 
all been negative in prior case reports.4-7 Only one of 
the ten cases has reported unfractionated heparin as 
an inciting agent for hemorrhagic bullosis,8 while the 
remaining have been from LMWH. The age range of 
affected patients in case reports were 50-90 years old 
with several having a history of malignancy.4-8
Hemorrhagic bullosis seems to take a clinically benign 
course with no patient report of pain or pruritis. The onset 
of bullae in our case is consistent with the reported 5 to 
21 day window of lesion development reported in the 
literature. The association between lesion regression 
and discontinuation of heparin treatment seems to 
be unclear given that about half of the patients’ bullae 
reported thus far regress despite continuation of 
heparin therapy with no changes in dosing. Although the 
resolution of bullae in our patient occurred several days 
after enoxaparin dose reduction, it is hard to differentiate 
whether lesion regression occurred directly due to 
medication management or the natural history of these 
seemingly benign, self-limiting, bullae. 
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